Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$95.50 USD

95.50
1,324,649

+1.07 (1.13%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $95.51 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

by Zacks Equity Research

Sector ETF report for ARKG

    Zacks Equity Research

    Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International

    by Zacks Equity Research

    Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International

      Tirthankar Chakraborty headshot

      4 Winning Stocks With Solid Efficiency Level

      by Tirthankar Chakraborty

      A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

        Zacks Equity Research

        Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA

        by Zacks Equity Research

        The FDA accepts Evoke Pharma's (EVOK) regulatory application seeking approval of its pipeline candidate, Gimoti, for treating diabetic gastroparesis. Shares up.

          Zacks Equity Research

          Accuray (ARAY) Earnings Beat in Q4, Gross Orders Rise Y/Y

          by Zacks Equity Research

          Accuray's (ARAY) flagship Radixact System drives Q4 results; overseas gains raise hope.

            Zacks Equity Research

            Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study

            by Zacks Equity Research

            Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.

              Zacks Equity Research

              Can Illumina (ILMN) Stock Continue to Grow Earnings?

              by Zacks Equity Research

              Illumina (ILMN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.

                Zacks Equity Research

                Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech

                by Zacks Equity Research

                Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.

                  Zacks Equity Research

                  Corcept (CORT) Earnings and Revenues Miss Estimates in Q2

                  by Zacks Equity Research

                  Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.

                    Zacks Equity Research

                    Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales

                    by Zacks Equity Research

                    Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.

                      Zacks Equity Research

                      Pacific Biosciences' Sequel Sees Solid Q2, Competition Rife

                      by Zacks Equity Research

                      Pacific Biosciences (PACB) gains from solid presence in Asia; competition likely to mar results.

                        Zacks Equity Research

                        Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag

                        by Zacks Equity Research

                        Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.

                          Zacks Equity Research

                          PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y

                          by Zacks Equity Research

                          PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.

                            Zacks Equity Research

                            OPKO Health (OPK) Earnings & Revenues Beat Estimates in Q2

                            by Zacks Equity Research

                            OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE; declining segmental revenues raise concern.

                              Zacks Equity Research

                              Wright Medical (WMGI) Beats on Q2 Earnings, Raises '18 View

                              by Zacks Equity Research

                              Growth in the upper and lower extremity segments drives Wright Medical's (WMGI) Q2 results.

                                Zacks Equity Research

                                Inovio (INO) Q2 Loss Narrows, Revenues Surpass Estimates

                                by Zacks Equity Research

                                Inovio's (INO) Q2 loss betters estimates. Also, the company rides high on revenue beat.

                                  Zacks Equity Research

                                  Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2

                                  by Zacks Equity Research

                                  Merrimack's (MACK) loss is wider than expected in Q2 but narrower than the year-ago quarter's deficit. Meanwhile, the company did not generate any revenues in the reported quarter.

                                    Zacks Equity Research

                                    CBM vs. ILMN: Which Stock Should Value Investors Buy Now?

                                    by Zacks Equity Research

                                    CBM vs. ILMN: Which Stock Is the Better Value Option?

                                      Zacks Equity Research

                                      Inogen (INGN) Beats on Q2 Earnings, Lifts '18 Sales Guidance

                                      by Zacks Equity Research

                                      Inogen (INGN) puts up solid segmental show in Q2; international sales surge.

                                        Zacks Equity Research

                                        Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View

                                        by Zacks Equity Research

                                        Surmodics' (SRDX) third-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.

                                          Zacks Equity Research

                                          DENTSPLY (XRAY) Beats on Q2 Earnings, Lowers 2018 Guidance

                                          by Zacks Equity Research

                                          DENTSPLY (XRAY) gains from solid year-over-year international revenue growth in Q2; high impairment charges in the quarter mars results.

                                            Zacks Equity Research

                                            Luminex (LMNX) Misses on Earnings in Q2, Margins Contract

                                            by Zacks Equity Research

                                            Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q2; a solid guidance encourages.

                                              Zacks Equity Research

                                              Allscripts (MDRX) Q2 Earnings In Line, Revenues Top Estimates

                                              by Zacks Equity Research

                                              Allscripts (MDRX) gains from solid segmental performance in Q2; a decline in bookings discourages.

                                                Zacks Equity Research

                                                Cardinal Health (CAH) Surpasses Earnings Estimates in Q4

                                                by Zacks Equity Research

                                                Cardinal Health (CAH) witnesses strong Q4, owing to strong sales at Pharmaceutical and the Medical segments. It provides an impressive FY19 view.

                                                  Zacks Equity Research

                                                  Quality Systems (QSII) Q1 Earnings & Revenues Beat Estimates

                                                  by Zacks Equity Research

                                                  Quality Systems (QSII) gains from solid bookings in Q2; growing pipeline encourages.